PT - JOURNAL ARTICLE AU - Hampras, Shalaka S. AU - Viscidi, Raphael P. AU - Helzlsouer, Kathy J. AU - Lee, Ji-Hyun AU - Fulp, William J. AU - Giuliano, Anna R. AU - Platz, Elizabeth A. AU - Rollison, Dana E. TI - Prospective Study of Seroreactivity to JC Virus T-Antigen and Risk of Colorectal Cancers and Adenomas AID - 10.1158/1055-9965.EPI-14-0370 DP - 2014 Nov 01 TA - Cancer Epidemiology Biomarkers & Prevention PG - 2591--2596 VI - 23 IP - 11 4099 - http://cebp.aacrjournals.org/content/23/11/2591.short 4100 - http://cebp.aacrjournals.org/content/23/11/2591.full SO - Cancer Epidemiol Biomarkers Prev2014 Nov 01; 23 AB - John Cunningham virus (JCV) is a common polyomavirus classified as a possible carcinogen by the International Agency for Research on Cancer. JCV may play a role in colorectal carcinogenesis, although we previously reported no association between JCV capsid antibodies and colorectal cancer. No studies have examined the role of seroreactivity to JCV T-antigen (T-Ag) oncoprotein in colorectal cancer. A case–control study nested within a community-based prospective cohort (CLUE II) was conducted. In 1989, 25,080 residents of Washington County, Maryland, were enrolled in CLUE II, completing baseline questionnaires and providing blood samples. At follow-up, 257 incident colorectal cancer cases were identified by linkage to population-based cancer registries through 2006 and matched to controls on age, sex, race, and date of blood draw. One hundred and twenty-three colorectal adenoma cases were identified through self-report during follow-up and matched to controls on age, sex, race, date of blood draw, and colorectal cancer screening. Baseline serum samples were tested for seroreactivity to JCV T-Ag. Associations between JCV T-Ag seroreactivity and colorectal cancer/adenomas were evaluated using conditional logistic regression models. Overall, seroreactivity to JCV T-Ag was not statistically significantly associated with the risk of either colorectal cancer [OR, 1.34; 95% confidence interval (CI), 0.89–2.01] or adenoma (OR, 1.30; 95% CI, 0.70–2.42), while a borderline association with colorectal cancer was observed among women (OR, 1.82; 95% CI, 1.00–3.31). Our past evaluation of JCV capsid seropositivity, combined with current findings, does not support a notable etiologic role for JCV infection in colorectal cancer. Cancer Epidemiol Biomarkers Prev; 23(11); 2591–6. ©2014 AACR.